ArticleFrontiers in endocrinology2025
Association of circulating 25-hydroxyvitamin D with time in range and insulin secretion in type 2 diabetes.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Synergistic Association of Glycemic Variability and Severe Vitamin D Deficiency with Proliferative Diabetic Retinopathy.Nutrients · 2025Article
- Vitamin D and Chronic Disorders: A Review of Metabolic and Cardiovascular Diseases.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To explore the association of circulating 25-hydroxyvitamin D [25(OH)D] with time in range and insulin secretion in type 2 diabetes. Methods: 911 patients diagnosed with type 2 diabetes mellitus (T2DM) were included, and they underwent 3-day continuous glucose monitoring (CGM) and serum 25(OH)D measurements. The subjects were categorized into three groups based on the tertiles of their serum 25(OH)D levels: G1 (25(OH)D ≤ 21.22 ng/mL), G2 (21.22 ng/mL ≤ 25(OH)D < 26.43 ng/mL), and G3 (25(OH)D ≥ 26.43 ng/mL). TIR and glycemic variability (GV) parameters were evaluated with CGM. Insulin resistance was evaluated via the homeostatic model assessment of insulin resistance (HOMA-IR). The pancreatic β-cell function was determined using the homeostasis model assessment of β-cell function (HOMA-β). Among the 911 enrolled subjects, 582 individuals underwent a 100g standardized steamed bread meal test to comprehensively evaluate the pancreatic β-cell secretory function. Results: A higher TIR and time in tight range (TITR) were observed among individuals in the upper tertile for 25(OH)D, surpassing those in the middle and lower tertiles. The results of correlation analysis revealed that serum 25(OH)D levels were significantly positively correlated with TIR and TITR. Conversely, serum 25(OH)D levels were negatively associated with time above range, GV parameters, hemoglobin A1c (HbA1c), and HOMA-IR. However, no significant association was observed between serum 25(OH)D levels and HOMA-β. Additionally, the correlation between 25(OH)D and TIR ( Conclusions: This study demonstrated that in patients with T2DM, 25(OH)D levels exhibited positive correlations with TIR and glucose-stimulated insulin secretion parameters, while showing negative correlations with GV parameters. Lower serum 25(OH)D levels may adversely impact glucose homeostasis and pancreatic β-cell secretory function in T2DM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.